Literature DB >> 34427495

Intrathecal Transplantation of Autologous and Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Dogs.

Felipe Pérez Benavides1, Giovana Boff Araujo Pinto1, Marta Cristina Thomas Heckler1, Diana Milena Rodríguez Hurtado2, Livia Ramos Teixeira3, Marina Mitie de Souza Monobe1, Gisele Fabrino Machado4, Guilherme Dias de Melo4, Diego Noé Rodríguez-Sánchez1, Fernanda da Cruz Landim E Alvarenga2, Rogério Martins Amorim1.   

Abstract

The route used in the transplantation of mesenchymal stem cells (MSCs) can directly affect the treatment success. The transplantation of MSCs via the intrathecal (IT) route can be an important therapeutic strategy for neurological disorders. The objective of this study was to evaluate the safety and feasibility of the IT transplantation of autologous (Auto-MSCs) and allogeneic (Allo-MSCs) bone marrow mesenchymal stem cells (BM-MSCs) in healthy dogs. Based on neurodisability score, cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI), no significant differences from the control group were observed on day 1 or day 5 after IT Auto- or Allo-MSCs transplantation (P > 0.05). In addition, analysis of matrix metalloproteinase (MMP)-2 and MMP-9 expression in the CSF revealed no significant differences (P > 0.05) at 5 days after IT transplantation in the Auto- or Allo-MSCs group when compared to the control. Intrathecal transplantation of BM-MSCs in dogs provides a safe, easy and minimally invasive route for the use of cell-based therapeutics in central nervous system diseases.

Entities:  

Keywords:  bone marrow mesenchymal stem cells; cell-based therapy; cerebrospinal fluid; intrathecal route; matrix metalloproteinase

Mesh：

Year:  2021        PMID： 34427495      PMCID： PMC8388229          DOI： 10.1177/09636897211034464

Source DB:  PubMed          Journal:  Cell Transplant        ISSN： 0963-6897            Impact factor:   4.064


  60 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

2.  Immunophenotype and gene expression profile of mesenchymal stem cells derived from canine adipose tissue and bone marrow.

Authors:  Rudell Screven; Elizabeth Kenyon; Michael J Myers; Haile F Yancy; Mark Skasko; Lynne Boxer; Elmer C Bigley; Dori L Borjesson; Min Zhu
Journal:  Vet Immunol Immunopathol       Date:  2014-07-01       Impact factor: 2.046

3.  Comparative study of methods for administering neural stem/progenitor cells to treat spinal cord injury in mice.

Authors:  Yuichiro Takahashi; Osahiko Tsuji; Gentaro Kumagai; Chikako Miyauchi Hara; Hirotaka James Okano; Atsushi Miyawaki; Yoshiaki Toyama; Hideyuki Okano; Masaya Nakamura
Journal:  Cell Transplant       Date:  2010-11-05       Impact factor: 4.064

4.  Comparisons of the therapeutic effects of three different routes of bone marrow mesenchymal stem cell transplantation in cerebral ischemic rats.

Authors:  Hong-Lian Zhang; Xu-Fang Xie; Ying-Qiong Xiong; Shi-Min Liu; Guo-Zhu Hu; Wen-Feng Cao; Xiao-Mu Wu
Journal:  Brain Res       Date:  2017-12-21       Impact factor: 3.252

5.  Cerebrospinal fluid analysis and magnetic resonance imaging in the diagnosis of neurologic disease in dogs: a retrospective study.

Authors:  Andrea A Bohn; Tamara B Wills; Chadwick L West; Russell L Tucker; Rodney S Bagley
Journal:  Vet Clin Pathol       Date:  2006-09       Impact factor: 1.180

6.  Matrix metalloproteinase-9 activity in the cerebrospinal fluid and serum of dogs with acute spinal cord trauma from intervertebral disk disease.

Authors:  Jonathan M Levine; Craig G Ruaux; Robert L Bergman; Joan R Coates; Jörg M Steiner; David A Williams
Journal:  Am J Vet Res       Date:  2006-02       Impact factor: 1.156

7.  Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.

Authors:  Dimitrios Karussis; Clementine Karageorgiou; Adi Vaknin-Dembinsky; Basan Gowda-Kurkalli; John M Gomori; Ibrahim Kassis; Jeff W M Bulte; Panayiota Petrou; Tamir Ben-Hur; Oded Abramsky; Shimon Slavin
Journal:  Arch Neurol       Date:  2010-10

Review 8.  Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications.

Authors:  S Zucker; M Hymowitz; C Conner; H M Zarrabi; A N Hurewitz; L Matrisian; D Boyd; G Nicolson; S Montana
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

9.  Comparison of two regimens for the treatment of meningoencephalomyelitis of unknown etiology.

Authors:  P M Smith; C E Stalin; D Shaw; N Granger; N D Jeffery
Journal:  J Vet Intern Med       Date:  2009 May-Jun       Impact factor: 3.333

Review 10.  Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.

Authors:  Manoj M Lalu; Lauralyn McIntyre; Christina Pugliese; Dean Fergusson; Brent W Winston; John C Marshall; John Granton; Duncan J Stewart
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240
View more
  2 in total

1.  The Long-Term Efficacy Study of Multiple Allogeneic Canine Adipose Tissue-Derived Mesenchymal Stem Cells Transplantations Combined With Surgery in Four Dogs With Lumbosacral Spinal Cord Injury.

Authors:  Chung-Chao Chen; Shu-Fang Yang; Ing-Kae Wang; Sing-Ying Hsieh; Jian-Xi Yu; Tze-Lien Wu; Wan-Jhen Huong; Min-Hao Su; Heng-Leng Yang; Pi-Chen Chang; Ann-Chi Teng; Chen Chia-Yi; Sao-Ling Liang
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

2.  Transplantation of IGF-1-induced BMSC-derived NPCs promotes tissue repair and motor recovery in a rat spinal cord injury model.

Authors:  Putri Nur Hidayah Al-Zikri; Tee Jong Huat; Amir Ali Khan; Azim Patar; Mohammed Faruque Reza; Fauziah Mohamad Idris; Jafri Malin Abdullah; Hasnan Jaafar
Journal:  Heliyon       Date:  2022-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.